169 related articles for article (PubMed ID: 27261586)
1. Advances in biomarkers of biliary tract cancers.
Hu J; Yin B
Biomed Pharmacother; 2016 Jul; 81():128-135. PubMed ID: 27261586
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
[TBL] [Abstract][Full Text] [Related]
3. Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y; Muramatsu T; Kanai Y; Ojima H; Sukeda A; Hiraoka N; Arai E; Sugiyama Y; Matsuzaki J; Uchida R; Yoshikawa N; Furukawa R; Saito H
Cell Rep; 2019 Apr; 27(4):1265-1276.e4. PubMed ID: 31018139
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of biliary tract cancer.
Sohal DP; Shrotriya S; Abazeed M; Cruise M; Khorana A
Crit Rev Oncol Hematol; 2016 Nov; 107():111-118. PubMed ID: 27823638
[TBL] [Abstract][Full Text] [Related]
6. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.
Letelier P; Riquelme I; Hernández AH; Guzmán N; Farías JG; Roa JC
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27223281
[TBL] [Abstract][Full Text] [Related]
7. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
9. Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol.
Rebersek M; Hribernik N; Markovic K; Markovic S; Valentinuzzi KU; Cemazar M; Zuliani T; Milacic R; Scancar J
Radiol Oncol; 2024 Jun; 58(2):300-310. PubMed ID: 38553250
[TBL] [Abstract][Full Text] [Related]
10. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359
[TBL] [Abstract][Full Text] [Related]
11. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy.
Palmieri LJ; Lavolé J; Dermine S; Brezault C; Dhooge M; Barré A; Chaussade S; Coriat R
Pharmacol Ther; 2020 Jun; 210():107517. PubMed ID: 32109491
[TBL] [Abstract][Full Text] [Related]
12. Surgical management of biliary tract cancers.
Fairweather M; Balachandran VP; D'Angelica MI
Chin Clin Oncol; 2016 Oct; 5(5):63. PubMed ID: 27829277
[TBL] [Abstract][Full Text] [Related]
13. Genetic alteration regulated by microRNAs in biliary tract cancers.
Wang N; Xia S; Chen K; Xiang X; Zhu A
Crit Rev Oncol Hematol; 2015 Nov; 96(2):262-73. PubMed ID: 26095617
[TBL] [Abstract][Full Text] [Related]
14. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers].
Goeppert B
Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for biliary tract cancers.
Faris JE; Zhu AX
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
[TBL] [Abstract][Full Text] [Related]
16. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
17. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
18. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
19. Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options.
Shoda J; Ishige K; Sugiyama H; Kawamoto T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):342-53. PubMed ID: 22678429
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of biliary tract cancer.
Chai Y
Tumour Biol; 2016 Mar; 37(3):2817-21. PubMed ID: 26729196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
